[Drug therapy of otitis externa and otitis media].
The objective of the present work was to analyse the available pharmaceutical products used for treatment of otitis media. The rational application of these medications makes it possible to eliminate rapidly a variety of etiological factors, reduce the severity of inflammation, and improve the quality of life of the patients. One of the approaches to the achievement of these goals for the patients with otitis externa and otitis media consists of the use of combined preparations containing antibacterial, antimycotic, anti-inflammatory and analgetic components. Candibiotic is a four-components drug composed of chloramphenicol, clotrimazol, beclomethasone and lidocaine. The advantages of Candibiotic include high therapeutic efficacy due to its ethiotropic and pathogenetic activity and safety as its components do not have ototoxicity in the case of local application).
S V
SV
Okovityĭ
D Iu
DIu
Ivkin
S V
SV
Malygin
D000287:Administration, Topical; D000779:Anesthetics, Local / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000935:Antifungal Agents / Q000008:administration & dosage*; D001507:Beclomethasone / Q000008:administration & dosage*; D002701:Chloramphenicol / Q000008:administration & dosage*; D003022:Clotrimazole / Q000008:administration & dosage*; D004338:Drug Combinations; D006801:Humans; D008012:Lidocaine / Q000008:administration & dosage*; D010032:Otitis Externa / Q000188:drug therapy*; D010033:Otitis Media / Q000188:drug therapy*
D000779:Anesthetics, Local; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000935:Antifungal Agents; D004338:Drug Combinations; D002701:Chloramphenicol; D008012:Lidocaine; D003022:Clotrimazole; D001507:Beclomethasone